ZEVTERA
LOE Approachingceftobiprole medocaril sodium
NDAINTRAVENOUSPOWDERPriority Review
Approved
Apr 2024
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEVTERA (ceftobiprole medocaril sodium) is a fifth-generation cephalosporin antibiotic administered intravenously as a powder for reconstitution. It is indicated for treating serious bacterial infections, including community-acquired bacterial pneumonia and other gram-positive and gram-negative infections. The drug works by inhibiting bacterial cell wall synthesis, making it bactericidal against a broad spectrum of pathogens.
LOE Approaching2.7 years to LOE
Recent 2024 approval positions ZEVTERA in early commercial expansion, but LOE approaching by 2029 signals limited career runway for brand-building roles; teams will focus on rapid penetration and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.